



ASX Announcement

1 October 2020

Dr Tom Duthy Appointed Executive Director

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) a clinical stage biopharmaceutical company re-purposing Exenatide for the treatment of pressure-related neurological disease, is pleased to announce the appointment of Dr Tom Duthy as an Executive Director of the Company effective 1 October 2020.

Dr Duthy is currently the CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations (IR) firm based in Adelaide, Australia. Dr Duthy was formerly the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (Sirtex), which was sold to CDH Investments in September 2018 for \$1.9 billion and remains the largest medical device transaction in Australian corporate history. He currently advises several ASX Listed companies in both IR and Corporate Development roles. At Nova Eye Medical Limited this included the recent completion of a \$100 million sale of the ophthalmic laser business to Lumibird Group SA.

Prior to Sirtex, Dr Duthy spent ten years as a leading sell-side Healthcare & Biotechnology analyst focused mainly on small cap companies. During this time, approximately \$200 million in equity capital was raised for selected portfolio companies. Dr Duthy holds a Ph.D from the University of Adelaide and an MBA from Deakin University. He is a Member of the Australian Institute of Company Directors and the Australasian Investor Relations Association. Dr Duthy is currently a Non-Executive Director of Respi Limited.

Dr Jason Loveridge, Executive Chairman of Invex commented “On behalf of my fellow Directors of Invex I am delighted to announce Tom’s appointment to the Board. Tom’s extensive financial market experience, coupled with his senior executive experience at the S&P/ASX Top 100 Company level and involvement in significant corporate transactions within the sector, will be invaluable as we execute on our corporate strategies and grow value for our shareholders.”

Pursuant to Dr Duthy’s appointment he will receive Executive Director remuneration equating to \$125,000 per annum. Additionally, the Company will issue 800,000 options in the Company with a strike price of \$1.30 and a term of 3 years with vesting at 12 months and 24 months employment with the Company. The issue of options will be subject to shareholder approval at the upcoming Annual General Meeting, expected to be held on 19 November 2020. The Company and Dr Duthy may terminate the Agreement on 30 days written notice.

Invex also advises Ms Narelle Warren will be resigning as a Director from 1 October 2020 but will retain Chief Financial Officer and Company Secretary responsibilities. The Board wishes to thank Narelle for her contribution to the Board and the Invex IPO in 2019.

This release dated 1 October 2020 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

For more information, please contact:

Company/Investors

Dr Thomas Duthy

Executive Director

tduthy@invextherapeutics.com

+61 402 493 727

Media

Margie Livingston

Ignite Communications

margie@ignitecommunications.com.au

+61 438 661 131

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.